DDrare: Database of Drug Development for Rare Diseases

Rituximab infusion (DrugBank: Rituximab)

2 diseases

ID	Disease name (Link within this page)	Number of trials
13	Multiple sclerosis/Neuromyelitis optica	1
222	Primary nephrotic syndrome	1

13. Multiple sclerosis/Neuromyelitis optica [ 3,050 clinical trials, 2,147 drugs, (DrugBank: 348 drugs), 244 drug target genes, 228 drug target pathways]

Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 3,050 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02040116 (ClinicalTrials.gov)	February 2013	14/1/2014	Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases	Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases	Multiple Sclerosis	Drug: Rituximab Infusion	Wake Forest University Health Sciences	NULL	Completed	18 Years	80 Years	All	19	Phase 4	United States

222. Primary nephrotic syndrome [ 234 clinical trials, 241 drugs, (DrugBank: 78 drugs), 59 drug target genes, 185 drug target pathways]

Searched query = "Primary nephrotic syndrome", "Minimal change nephrotic syndrome", "MCNS", "Membranous nephropathy", "Focal segmental glomerulosclerosis", "FSGS", "Membranoproliferative glomerulonephritis", "MPGN"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 234 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00977977 (ClinicalTrials.gov)	December 2, 2010	15/9/2009	Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy	Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy	Nephrotic Syndrome;Proteinuria;Autoimmune Disease;Glomerular Disease;Membranous Glomerulonephritis	Drug: Rituximab Infusion;Drug: Oral Cyclosporine	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	NULL	Recruiting	18 Years	100 Years	All	30	Phase 2	United States